Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Lasofoxifene Improves Symptoms of Vaginal Atrophy in Postmenopausal Women: Presented at NAMS By Deborah Brauser ORLANDO, Fla -- September 30, 2008 -- Lasofoxifene, a selective oestrogen receptor module (SERM), demonstrated significant improvements in vaginal atrophy in osteoporotic postmenopausal women by decreasing vaginal pH and improving the vaginal-cell maturation index, according to trial results presented here at the North American Menopause Society (NAMS) 19th Annual Meeting. Steven Goldstein, MD, New York University School of Medicine, New York, New York, reported the results of a 3-year, phase 3 study of lasofoxifene in a late-breaking poster presentation here on September 25. In the Postmenopausal Evaluation and Risk-Reduction With Lasofoxifene (PEARL) study, 8,556 postmenopausal women with osteoporosis were given calcium (1,000 mg) and vitamin D (400-800 IU), and then randomly assigned to lasofoxifene dosage groups of either 0.25 or 0.5 mg/d, or placebo. All subjects were aged 59 to 80 years. A subset of 326 subjects from the PEARL trial was further assessed for vaginal pH and maturation index at baseline, 12 months, 24 months, and 36 months. At the end of the trial, lasofoxifene treatment in the subset decreased pH log units -0.27 (95% CI, -0.38 to -0.16; P = .001) for the 0.25-mg dose and -0.13 (95% CI, -0.25 to -0.02; P = .001) for the 0.5-mg dose, compared with placebo. In addition, a significant effect was seen at 12 months in both dosage groups and was sustained throughout the study. Both lasofoxifene groups also showed positive effects on the vaginal-cell maturation index, with an increase in superficial cells relative to parabasal cells at 12 months and sustained through 3 years. Additionally, shifts towards a lower proportion of parabasal cells, and greater proportions of intermediate and superficial cells were observed after both lasofoxifene treatments, while the relative proportion of parabasal, intermediate, and superficial cells remained generally unchanged in the placebo group. Said Dr. Goldstein, "This really is the first SERM that seems to have a positive effect on objective findings in the vagina. So, whereas, in my clinical practice, pretty much every patient on raloxifene is also on an intravaginal oestrogen, a significant number of women theoretically on a drug like this would not need a second drug in the vagina because of the improvements in the vaginal effects." "Here's a SERM that has a different action in the vagina than the ones we're familiar with," added Dr. Goldstein. Funding for this trial was provided by Pfizer, Inc. [Presentation title: Vaginal Effects of Lasofoxifene: 3-Year Results From the PEARL Trial. Abstract LB-5] E-mail this page to a friend or colleague! To print, use this version